Schering/Zonagen end Vasomax agreement
Executive Summary
Schering-Plough and Zonagen mutually terminate worldwide licensing agreement for experimental oral erectile dysfunction therapy Vasomax and other phentolamine-based technologies, Zonagen announces July 15. The decision coincides with the submission of final results from a one-year mechanistic study of phentolamine-induced brown fat proliferations in rats, which Zonegan maintains show no effect. The study was designed to allay FDA's concerns raised by an earlier two-year rat carcinogenicity trial; FDA deemed Vasomax "not approvable" in May 1999 and subsequently placed the drug on clinical hold (1"The Pink Sheet" Aug. 16, 1999, p. 32)...
You may also be interested in...
Zonagen/Schering-Plough Vasomax
FDA places hold on clinical trials of Vasomax (phentolamine) pending analysis of data from a two-year rat carcinogenicity study, expected to be completed in the fourth quarter. Preliminary findings show a high proliferation of "brown fat" in the rats. A fully enrolled, 12-week Schering study of Vasomax for erectile dysfunction has been permitted to continue. Another proposed 12-week Schering study and a Zonagen Phase II trial of phentolamine for female sexual dysfunction are being placed on hold. The companies anticipate the hold will cause a six-month delay in regulatory filing
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.